-
The Autism spectrum disorder candidate genes SATB2, CHD8 and EHMT1 show enriched expression in neurons, especially inhibitory neurons
-
up-regulation of miR-31 may underlie endothelial dysfunction in diabetes by targeting Satb2
-
SATB2 as an additional diagnostic marker for the diagnosis of an ovarian manifestation of low-grade appendiceal mucinous neoplasm
-
HNF4-alpha and particularly SATB2 may be helpful in the differential diagnosis of pulmonary adenocarcinoma and metastases of colorectal adenocarcinomas
-
The study identified that decreased expression of SATB2 was correlated with tumor progression and poor prognosis in non-small cell lung cancer (NSCLC) patients. Furthermore, SATB2 suppressed lung cancer cell invasion and metastasis and regulated the expression of EMT-related proteins and histone methylation by G9a.
-
this study shows that SATB2 is a diagnostic marker of sinonasal intestinal-type adenocarcinoma
-
SATB2 could serve as a promising diagnostic biomarker of colorectal cancer metastases.
-
SATB2 can be used as a supplementary marker along with CDX2 to identify 'colon-rectum' as the primary site in material from patients presenting with metastasis.
-
We describe the phenotype and genotype of 12 individuals with 10 unique (de novo in 11 of 11 tested) pathogenic variants (1 splice site, 5 frameshift, 3 nonsense, and 2 missense) in SATB2 and review all cases reported in the published literature caused by point alterations thus far
-
features associated with de novo mutations affecting SATB2 function in individuals ascertained on the basis of intellectual disability
-
The mRNA level of SATB2 was lower in tumor tissues than in samples of corresponding unchanged kidney. The results of the presented study suggest the tumor-suppressing function of SATB2.
-
MiR-875-5pdirectly binds to the 3'untranslated region of SATB.2
-
These results strongly suggest that SATB2 prevents induction of EMT by suppressing expression of EMT-inducing transcription factors in NSCLC cells.
-
We describe here the identification of a de novo SATB2 point mutation in twin boys with cleft soft palate, dental anomalies, and development delay and compare the clinical presentation of SATB2 point mutation patients reported to date.
-
our data reveal that SATB2 in alveolar bone mesenchymal stem cells (AB-BMSCs) associates with their age-related properties, and prevents AB-BMSCs senescence via maintaining Nanog expression.
-
SATB2 is frequently expressed in appendiceal mucinous neoplasms. In the context of a mucinous neoplasm involving the ovary, any SATB2 positivity should raise the possibility of appendiceal origin.
-
our results strongly indicate that the crosstalk between p38 and Akt pathways can determine special AT-rich sequence-binding protein 2 expression and epithelial character of non-small-cell lung carcinoma cells
-
SATB2 immunohistochemistry is not useful in supporting urothelial versus gastrointestinal or endocervical origin in the differential diagnosis of glandular lesions of the bladder/urinary tract.
-
we report a exon frameshift mutation in SATB2 in a 15-year-old patient with cleft palate, apparent ID, mild facial dysmorphism, and low weight with additional features of osteoporosis, fractures, progressive tibial bowing, and scoliosis. it provides further evidence of a single-nucleotide, potentially dominant-negative SATB2 allele in association with phenotypes beyond those typically associated with deletion of the gene
-
Indicate that beta-catenin and SATB2 are useful immunohistochemical markers for differentiating between pulmonary enteric adenocarcinoma and metastatic colorectal carcinoma.
